Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

02 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251002836097/en/Newron-to-Present-New-Analyses-From-and-Updates-on-its-Clinical-Program-Evaluating-Evenamide-as-an-Add-on-Treatment-for-Schizophrenia-at-the-38th-European-College-of-Neuropsychopharmacology-ECNP-Congress-2025

16 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-16/newron-presents-h1-2025-results-and-provides-business-update

05 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-05/newron-to-present-data-and-updates-on-its-clinical-program-evaluating-evenamide-as-an-add-on-treatme

12 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250812127452/en/Newron-Begins-Enrollment-in-Pivotal-Phase-III-ENIGMA-TRS-Program-With-Evenamide-as-Add-on-Therapy-in-Patients-With-Treatment-Resistant-Schizophrenia-TRS

11 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250811493586/en/Newron-Notes-the-Publication-of-New-Preclinical-Research-Suggesting-Evenamide-Ameliorates-Schizophrenia-Related-Dysfunction

11 Aug 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-08-11/newron-notes-the-publication-of-new-preclinical-research-suggesting-evenamide-ameliorates-schizophre
ABOUT THIS PAGE